Ultragenyx Pharmaceutical (NASDAQ:RARE) – Stock analysts at SunTrust Banks boosted their FY2018 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a report released on Wednesday, April 18th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings per share of ($6.59) for the year, up from their prior forecast of ($6.63). SunTrust Banks currently has a “Buy” rating and a $55.00 target price on the stock. SunTrust Banks also issued estimates for Ultragenyx Pharmaceutical’s Q4 2018 earnings at ($1.63) EPS, FY2019 earnings at ($5.53) EPS, FY2020 earnings at ($5.28) EPS, FY2021 earnings at $0.23 EPS and FY2022 earnings at $5.70 EPS.
Several other brokerages have also recently issued reports on RARE. JPMorgan Chase reissued an “overweight” rating and issued a $66.00 price objective (down previously from $68.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Evercore ISI raised Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating in a report on Monday, January 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $74.00 price objective (down previously from $85.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. ValuEngine raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th. Finally, BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $69.76.
Shares of RARE stock opened at $54.26 on Friday. The stock has a market capitalization of $2,672.27, a PE ratio of -7.23 and a beta of 1.83. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $71.99.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.00) by ($0.27). The firm had revenue of $2.41 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the previous year, the business posted ($1.75) earnings per share.
Several institutional investors have recently made changes to their positions in RARE. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 1,246.9% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 3,030 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $156,000. Xact Kapitalforvaltning AB purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $205,000. B. Riley Financial Inc. purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $213,000. Finally, Aperio Group LLC purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $254,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/22/brokers-set-expectations-for-ultragenyx-pharmaceuticals-fy2018-earnings-rare.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.